Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03818854 · ClinicalTrials.gov registry record · Phase 2
Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome
A Phase 2 study, sponsored by Michael A. Matthay.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT03818854 is a Phase 2 study that has completed, run by Michael A. Matthay. The registered enrollment target is 120 participants.
The verdict
NCT03818854, a Phase 2 study, has completed, sponsored by Michael A. Matthay.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS). This study is the extension of the Phase 1 pilot study (NCT01775774) and Phase 2a study (NCT02097641).
Interventions
- BIOLOGICAL Human Mesenchymal Stromal Cells
- BIOLOGICAL Cell Reconstitution Media
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-11-26 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03818854
The ClinicalTrials.gov registry entry for NCT03818854 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael A. Matthay, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Human Mesenchymal Stromal Cells is the first listed.
NCT03818854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03818854 about?
NCT03818854 is a clinical study titled "Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome". This is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS). This study is the ex...
What is the current status of trial NCT03818854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2019-11-26. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT03818854?
The interventions under investigation include: Human Mesenchymal Stromal Cells (BIOLOGICAL), Cell Reconstitution Media (BIOLOGICAL).
Who is sponsoring clinical trial NCT03818854?
This trial is sponsored by Michael A. Matthay, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.